Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Holding BCLI?
Track your performance easily
BCLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $11.88
Previous Close$1.24
Volume44.28K
Average Volume (3M)72.94K
Market Cap
$7.07M
Enterprise Value$4.57M
Total Cash (Recent Filing)$3.47M
Total Debt (Recent Filing)$962.00K
Price to Earnings (P/E)―
Beta3.70
Next Earnings
Mar 27, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding5,703,426
10 Day Avg. Volume170,705
30 Day Avg. Volume72,939
Standard Deviation0.30
R-Squared0.00446
Alpha-0.00170
Financial Highlights & Ratios
Price to Book (P/B)-2.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Brainstorm Cell Therapeutics News
PremiumCompany Announcements
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials
Ownership Overview
24.66% Insiders
26.28% Mutual Funds
2.56% Other Institutional Investors
44.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $1.05 and its highest was $11.88 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Currently, no data Available
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 124 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.575 by $0.065.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Overvalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 5,703,426 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.575. Following the earnings report the stock price went up 7.08%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
---
Brainstorm Cell Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $11.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-64.36%
Trailing 12-Months
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
---
BCLI Earnings Call
Q2 2024
0:00 / 0:00
---
BCLI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering BCLI
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-77.46%
reiterated a buy rating 25 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -77.46% per trade.
---